All In Biotech

Drug Trial Radar · NCT02571036

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Dec 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

282

Actual

Start

Nov 2015

Primary completion

Apr 29, 2022

Study completion Apr 29, 2022

Sponsor

Lead sponsor
Deciphera Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Oct 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.

Conditions

  • Gastrointestinal Stromal Tumors
  • Advanced Systemic Mastocytosis
  • Advanced Cancers

Interventions

  • DCC-2618Drug

    50 mg formulated tablets

  • DCC-2618Drug

    10 mg and 50 mg formulated tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety/tolerability of oral DCC-2618: incidence of adverse eventsTime frame: Approximately 24 months
  2. Determination of the Maximum Tolerated Dose and the Recommended Phase 2 DoseTime frame: 18 months
  3. Expansion Phase: Assess Antitumor Activity of DCC-2618 in all diseasesTime frame: Approximately 24 months

Locations

26 sites in 6 countries. Site status is shown where the registry gives one.

  • Honor Health (GIST, mastocytosis, other solid tumors)

    Scottsdale, Arizona

  • UCLA Hematology Center (mastocytosis)

    Los Angeles, California

  • UCLA (glial malignancies only)

    Los Angeles, California

  • Stanford University Comprehensive Cancer Center (GIST)

    Palo Alto, California

  • Stanford University Hematology Clinic (mastocytosis)

    Palo Alto, California

  • UCSF (glial malignancies only)

    San Francisco, California

  • Mayo Clinic (GIST, mastocytosis, glial malignancies, other solid tumors)

    Jacksonville, Florida

  • University of Miami (GIST, mastocytosis, glial malignancies, other solid tumors)

    Miami, Florida

  • Dana Farber Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors)

    Boston, Massachusetts

  • Colombia University Medical Center (mastocytosis)

    New York, New York

  • Memorial Sloan Kettering Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)

    New York, New York

  • OHSU (GIST & mastocytosis only)

    Portland, Oregon

  • Fox Chase Cancer Center (GIST only)

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)

    Houston, Texas

  • Huntsman Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors)

    Salt Lake City, Utah

  • Virginia Commonwealth University School of Medicine (mastocytosis)

    Richmond, Virginia

  • Princess Margaret Cancer Centre (GIST, other solid tumors)

    Toronto, Canada

  • Uniklinik RWTH Aachen (mastocytosis, GIST, and other solid tumors)

    Aachen, Germany

  • HELIOS Klinikum Berlin-Buch (GIST, and other solid tumors)

    Berlin, Germany

  • Essen University Hospital (mastocytosis, GIST, and other solid tumors)

    Essen, Germany

  • Freiburg University Hospital (mastocytosis, and other solid tumors)

    Freiburg im Breisgau, Germany

  • University Medical Centre Mannheim (mastocytosis)

    Mannheim, Germany

  • University Hospital of Verona (mastocytosis)

    Verona, Italy

  • Leiden University Medical Center (GIST and other solid tumors)

    Leiden, Netherlands

  • Guy's Hospital (mastocytosis only)

    London, United Kingdom

  • Royal Marsden Hospital (GIST, glial malignancies, other solid tumors)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.